Advanced Search

Technical Analysis for CTIC - Cell Therapeutics, Inc.

Grade Last Price % Change Price Change
F 2.53 4.98% 0.12
CTIC closed up 4.98 percent on Wednesday, April 14, 2021, on 1.29 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
7 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical CTIC trend table...
Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Hammer Candlestick Bullish 4.98%
Lizard Bullish Bullish Day Trade Setup 4.98%
Doji - Bullish? Reversal 4.98%
Wide Bands Range Expansion 4.98%
Oversold Stochastic Weakness 4.98%
Fell Below 200 DMA Bearish 4.12%
180 Bearish Setup Bearish Swing Setup 4.12%
Inside Day Range Contraction 4.12%
Older End-of-Day Signals for CTIC ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 14 hours ago
Up 5% about 14 hours ago
2x Volume Pace about 14 hours ago
Lizard Bullish Entry about 15 hours ago
Hammer Candlestick Entry about 15 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators Basic chart:

Profile

Cell Therapeutics, Inc. Description

Cell Therapeutics, Inc. engages in the acquisition, development, and commercialization of treatments for cancer. The company primary focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative, which is in Phase III clinical trials for the treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphoma. It is also developing Opaxio, a chemotherapeutic agent that is in Phase III clinical trials for the treatment of ovarian cancer; in Phase II clinical trials for the treatment of malignant brain cancer; and in Phase I-II clinical trials for the treatment of head and neck cancer. In addition, the company is developing Pacritinib, a Janus kinase 2 inhibitor that is in Phase III clinical trials for the treatment of myelofibrosis; Tosedostat, an aminopeptidase inhibitor that is in Phase I-II clinical trials for the treatment of acute myeloid leukemia; and Brostallicin, which is in Phase II clinical trials for the treatment of triple-negative breast cancer. It has a license and co-development agreement with Chroma Therapeutics, Ltd. to develop and commercialize Tosedostat. Cell Therapeutics, Inc. was founded in 1991 and is headquartered in Seattle, Washington.

Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Chemical Compounds Organic Compounds Lymphoma Cancer Treatments Breast Cancer Treatment Of Breast Cancer Ovarian Cancer Acute Myeloid Leukemia Ethers Antibody Drug Conjugates Head And Neck Cancer Janus Brain Cancer Treatment Of Acute Myeloid Leukemia Treatment Of Ovarian Cancer Hodgkin Lymphoma Pyrrolidines Triple Negative Breast Cancer Camidanlumab Tesirine Janus Kinase Myelofibrosis Pacritinib Pixantrone Treatment Of Head And Neck Cancer

Is CTIC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Apr 10 The Past Week's Notable Insider Buys Included Biotechs, Public Offerings, A SPAC And More
Apr 7 CTI BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, Apr. 14
Apr 5 48 Biggest Movers From Thursday
Apr 1 CTI BioPharma secures $51M capital raise
Apr 1 CTI BioPharma Corp. Announces Pricing of its Public Offering of Common Stock and Preferred Stock
Mar 31 CTI BioPharma down 11% on proposing public offering
Mar 31 CTI BioPharma Corp. Announces Proposed Public Offering of Common Stock and Preferred Stock
Mar 31 CTI Biopharma completes rolling NDA submission of pacritinib in bone marrow cancer
Mar 31 CTI BioPharma Announces Completion of Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia
Mar 27 The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week
See more CTIC news...

Indicators

Indicator Value
52 Week High 4.13
52 Week Low 0.86
Average Volume 1,102,015
200-Day Moving Average 2.59
50-Day Moving Average 3.10
20-Day Moving Average 2.78
10-Day Moving Average 2.56
Average True Range 0.22
ADX 10.33
+DI 25.66
-DI 24.23
Chandelier Exit (Long, 3 ATRs ) 3.48
Chandelier Exit (Short, 3 ATRs ) 2.95
Upper Bollinger Band 3.36
Lower Bollinger Band 2.19
Percent B (%b) 0.29
BandWidth 41.88
MACD Line -0.19
MACD Signal Line -0.17
MACD Histogram -0.0163
Fundamentals Value
Market Cap 186.59 Million
Num Shares 73.8 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -4.11
Price-to-Sales 87.01
Price-to-Book 5.56
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.76
Resistance 3 (R3) 2.74 2.65 2.72
Resistance 2 (R2) 2.65 2.59 2.66 2.70
Resistance 1 (R1) 2.59 2.56 2.62 2.61 2.69
Pivot Point 2.50 2.50 2.52 2.51 2.50
Support 1 (S1) 2.44 2.44 2.47 2.46 2.37
Support 2 (S2) 2.35 2.41 2.36 2.36
Support 3 (S3) 2.29 2.35 2.34
Support 4 (S4) 2.31